|By PR Newswire||
|September 1, 2014 02:00 AM EDT||
MAINZ, Germany, September 1, 2014 /PRNewswire/ --
Mainz biopharmaceutical company BioNTech AG has announced that as of September 1, 2014 Mr. Sierk Pötting will join the management team of BioNTech AG as CFO (Chief Financial Officer), succeeding former CFO Mr. Michael Kring.
Sierk Pötting draws on many years of experience. After completing his degree and postdoctoral work in quantum physics, he began his career as a consultant with the company McKinsey before moving over to work with Novartis. For the past several years, Mr. Pötting has served as CFO and Vice President at Sandoz, Inc. in the USA.
"In my view, BioNTech is one of today's most exciting cancer research groups using integrated diagnostic and immunotherapeutic technologies. I am thrilled to have the opportunity to join this company on its journey to the future," explained Sierk Pötting.
Helmut Jeggle, chair of the supervisory board at BioNTech AG, commented: "We are very pleased to strengthen our management team with someone with his background and look forward to working with Mr. Pötting. The timing of his joining BioNTech is perfect for the company's development - Sierk will help us position the company strongly for the long term."
Mr. Michael Kring has made a significant contribution to the establishment of the BioNTech group since 2009 - first as a consultant and since 2010 as CFO. It is planned that he will remain with the company until the end of 2014 as a member of the board at BioNTech AG.
Prof. Ugur Sahin, board member, added: "I would like to warmly thank Michael Kring for his excellent work. Michael has made a very important contribution to the development of the company.
"I am looking forward to working together with Sierk Pötting, whose expertise and many years of experience in the industry will benefit the future of BioNTech."
BioNTech AG (Biopharmaceutical New Technologies) develops innovative immunotherapies to stimulate the body's immune system in the targeted fight against a number of different cancers and other major diseases. Several subsidiaries operate under the umbrella of the holding, each with their own business model and technology and patent portfolios. The company has a wide range of target structures specific to cancer at its disposal and makes use of proprietary technology platforms for the development of drugs that are designed specifically against these target structures.
SOURCE BioNTech AG
Oct. 26, 2016 12:00 AM EDT Reads: 1,034
Oct. 26, 2016 12:00 AM EDT Reads: 3,843
Oct. 26, 2016 12:00 AM EDT Reads: 34,216
Oct. 26, 2016 12:00 AM EDT Reads: 3,187
Oct. 25, 2016 11:45 PM EDT Reads: 2,988
Oct. 25, 2016 10:45 PM EDT Reads: 981
Oct. 25, 2016 10:15 PM EDT Reads: 983
Oct. 25, 2016 09:15 PM EDT Reads: 881
Oct. 25, 2016 08:45 PM EDT Reads: 2,709
Oct. 25, 2016 08:45 PM EDT Reads: 3,243
Oct. 25, 2016 08:30 PM EDT Reads: 1,104
Oct. 25, 2016 08:15 PM EDT Reads: 1,375
Oct. 25, 2016 07:30 PM EDT Reads: 1,543
Oct. 25, 2016 07:30 PM EDT Reads: 1,119
OnProcess Technology has announced it will be a featured speaker at @ThingsExpo, taking place November 1 - 3, 2016, in Santa Clara, California. Dan Gettens, OnProcess’ Chief Analytics Officer, will discuss how Internet of Things (IoT) data can be leveraged to predict product failures, improve uptime and slash costly inventory stock. @ThingsExpo is an annual gathering of IoT and cloud developers, practitioners and thought-leaders who exchange ideas and insights on topics ranging from Big Data in...
Oct. 25, 2016 07:15 PM EDT Reads: 313